Patents by Inventor Kirsten EDWARDS

Kirsten EDWARDS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD131 binding proteins and uses thereof
    Patent number: 11840573
    Abstract: The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: December 12, 2023
    Assignee: CSL LIMITED
    Inventors: Catherine Owczarek, Con Panousis, Nicholas Wilson, Matthew Hardy, Kirsten Edwards, Veronika Rayzman
  • HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
    Publication number: 20230086472
    Abstract: A serum albumin variant, or functional fragment thereof, comprising, one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Application
    Filed: August 30, 2022
    Publication date: March 23, 2023
    Applicant: CSL Limited
    Inventors: Sabine RAUTH, Andrew HAMMET, Kirsten Edwards, Con PANOUSIS
  • Human serum albumin variants and uses thereof
    Patent number: 11466073
    Abstract: A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 11, 2022
    Assignee: CSL Limited
    Inventors: Sabine Rauth, Andrew Hammet, Kirsten Edwards, Con Panousis
  • CD131 BINDING PROTEINS AND USES THEREOF
    Publication number: 20210324091
    Abstract: The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.
    Type: Application
    Filed: November 20, 2020
    Publication date: October 21, 2021
    Inventors: Catherine OWCZAREK, Kosta PANOUSIS, Nicholas WILSON, Matthew HARDY, Kirsten EDWARDS, Veronika RAYZMAN
  • CD131 binding proteins
    Patent number: 10894834
    Abstract: The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: January 19, 2021
    Assignee: CSL LIMITED
    Inventors: Catherine Owczarek, Kosta Panousis, Nicholas Wilson, Matthew Hardy, Kirsten Edwards, Veronika Rayzman
  • HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
    Publication number: 20200325209
    Abstract: A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Application
    Filed: October 18, 2018
    Publication date: October 15, 2020
    Applicant: CSL Limited
    Inventors: Sabine RAUTH, Andrew HAMMET, Kirsten EDWARDS, Con PANOUSIS
  • CD131 BINDING PROTEINS AND USES THEREOF
    Publication number: 20190062438
    Abstract: The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.
    Type: Application
    Filed: November 25, 2016
    Publication date: February 28, 2019
    Inventors: Catherine OWCZAREK, Kosta PANOUSIS, Nicholas WILSON, Matthew HARDY, Kirsten EDWARDS, Veronika RAYZMAN
  • Fibronectin III domain of IL-11R?
    Patent number: 9796782
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: October 24, 2017
    Assignee: CSL LIMITED
    Inventors: Kirsten Edwards, Matthew Hardy, Veronika Rayzman, Michael Wilson
  • IL-11R binding proteins
    Patent number: 9340618
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: May 17, 2016
    Assignee: CSL LIMITED
    Inventors: Kirsten Edwards, Matthew Hardy, Veronika Rayzman, Michael Wilson
  • IL-11R BINDING PROTEINS
    Publication number: 20160031999
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 4, 2016
    Applicant: 45 Poplar Road
    Inventors: Kirsten EDWARDS, Matthew HARDY, Veronika RAYZMAN, Michael WILSON
  • IL-11R BINDING PROTEINS AND USES THEREOF
    Publication number: 20140219919
    Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 7, 2014
    Applicant: CSL Limited
    Inventors: Kirsten EDWARDS, Matthew HARDY, Veronika RAYZMAN, Michael WILSON